Biogen Inc. (BIIB) News

Biogen Inc. (BIIB): $308.88

3.98 (+1.31%)

POWR Rating

Component Grades








Add BIIB to Watchlist
Sign Up

Industry: Biotech




#3 of 382

in industry

Filter BIIB News Items

BIIB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BIIB News Highlights

  • BIIB's 30 day story count now stands at 23.
  • Over the past 23 days, the trend for BIIB's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • DRUG, DNLI and ADD are the most mentioned tickers in articles about BIIB.

Latest BIIB News From Around the Web

Below are the latest news stories about BIOGEN INC that investors may wish to consider to help them evaluate BIIB as an investment opportunity.

Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122

Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's

Yahoo | June 6, 2023

Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure

In its ongoing R&D reorganization, Biogen Inc (NASDAQ: BIIB) will discontinue a Phase 3 program evaluating BIIB122 as a treatment for patients with Parkinson’s disease related to LRRK2 mutations with partner Denali Therapeutics Inc (NASDAQ: DNLI). Before the planned revisions, the BIIB122 development program encompassed the following: The Phase 2b LUMA study in participants with early-stage Parkinson’s disease commenced in May 2022. The Phase 3 LIGHTHOUSE study in participants with Parkinson’s d

Yahoo | June 5, 2023

10 Dementia Medications that are Approved or in Clinical Trials

In this article, we will be taking a look at the 10 dementia medications that are approved or in clinical trials. To skip our detailed analysis, you can go directly to see the 5 dementia medications that are approved or in clinical trials. Advancements in medicine have absolutely changed the way we live right now, […]

Yahoo | June 4, 2023

Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study

Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.

Yahoo | June 2, 2023

Medicare Plans to Cover Alzheimer’s Drugs

Medicare plans to widen coverage of Alzheimer’s drugs that could win full approval as soon as this summer. The Centers for Medicare and Medicaid Services on Thursday said it would cover Biogen and Eisai treatment Leqembi if the drug wins full approval and patients and doctors contribute to a registry that collects evidence on how the medication works. Most Alzheimer’s patients in the U.S. are Medicare enrollees.

Yahoo | June 1, 2023

Biogen Hits Buy Zone On A Fresh Win For Its Alzheimer's Treatment; Eli Lilly, Eisai Shares Jump

Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.

Yahoo | June 1, 2023

Medicare Will Pay for Biogen’s Alzheimer’s Drug, With a Caveat

The agency that oversees the medical program for seniors will pick up the bill only if doctors submit treatment data to a nationwide registry.

Yahoo | June 1, 2023

15 Best Healthcare Stocks To Buy Now

In this article, we will take a look at the 15 best healthcare stocks to buy now. For more stocks, head on over to 5 Best Healthcare Stocks To Buy Now. In the midst of uncertain economic conditions globally, the healthcare sector has displayed a notable degree of resilience. Historically, the demand for healthcare products […]

Yahoo | June 1, 2023

Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?

A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers. | May 30, 2023

Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 88% of the company

Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...

Yahoo | May 29, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7691 seconds.